Anti-Mouse CD29 (Clone KMI6) – Biotin
Anti-Mouse CD29 (Clone KMI6) – Biotin
Product No.: C1103
- -
- -
Clone KMI6 Target CD29 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Integrin beta-1, Fibronectin receptor subunit beta, VLA-4 subunit beta Isotype Rat IgG2a κ Applications ELISA , EM , FA , FC , IF Microscopy , IP , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Immunogen B cell-supportive stromal cell line BMS2 Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. State of Matter Liquid Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? ELISA, EM, FA, FC, IF microscopy, IP, WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity KMI6 activity is directed against mouse CD29, also known as integrin beta 1. Background Stromal cells are needed for the early steps of B lymphocyte differentiation and proliferation1.
CD29, also known as integrin beta 12, is a 110 kDa protein discovered due to its expression on
bone marrow stromal cells, at cell surface areas that interact with undifferentiated lymphoid cells1. Integrin beta 1 is a member of a family of alpha beta heterodimers that act as cell surface
receptors for extracellular matrix proteins3, including collagen, fibronectin, fibrinogen, laminin,
VCAM1, and vitronectin among others4. CD29 is also involved in sperm-egg fusion. Through
these interactions, CD29 regulates and/or promotes cell adhesion, laminin matrix deposition,
endothelial cell motility, angiogenesis, osteoblast compaction, the formation of mineralized bone
nodules, and cytokinesis. KMI6 was raised against the B cell-supportive stromal cell line BMS21. LOU/MN rats were immunized with BMS2 cells and subsequently spleen cells were fused with murine Sp2/0 for hybridoma generation. Antibody recognition is insensitive to the glycosylation state but is lost when the CD29 protein is reduced for Western blotting2. As such, the epitope is likely conformation-dependent. KMI6 was used to identify CD292. KMI6 can enhance cell adhesion of fibronectin to CD4 -8- thymocytes3. Antigen Distribution CD29 is present on the plasma membranes of many stromal cells, bone
marrow stromal cell line BMS2 in vitro, and a small number of cells in bone marrow cell
suspensions from adult mice. CD29 is also expressed in the media layer of the arterial wall.
CD29 is expressed in skeletal and cardiac muscles. CD29 is also constitutively expressed by
some immature thymocytes. CD29 can be slightly induced on mature thymocytes and peripheral
T cells by activation with Con A. Ligand/Receptor Alpha-1, alpha-2, alpha-3, alpha-4, alpha-5, alpha-6, alpha-7, alpha-8, alpha-9, alpha-10, alpha-11 or alpha-V, collagen, fibronectin, fibrinogen, laminin, VCAM1, and vitronectin among other NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Immunology . Integrin References & Citations1. Jacobsen K, Miyake K, Kincade PW, et al. J Exp Med. 176(4):927-935. 1992. 2. Wu X, Miyake K, Medina KL, et al. Hybridoma. 13(5):409-416. 1994. 3. Wadsworth SA, Chang AC, Hong MJ, et al. J Immunol. 154(5):2125-2133. 1995. 4. https://www.uniprot.org/uniprotkb/P09055/entry Technical ProtocolsCertificate of Analysis |
Formats Available
